Paper Details

  1. Home
  2. Paper Details

Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.

Author: , BoenteCharline S, CotterSusan A, DeanTrevano W, DosunmuEniolami O, FreedmanSharon F, GoldenRichard P, HartnettM Elizabeth, HolmesJonathan M, KongLingkun, KrakerRaymond T, LiZhuokai, PrakalapakornS Grace, RepkaMichael X, SmithLois E, WallaceDavid K, WangHaibo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Intravitreal bevacizumab doses as low as 0.002 mg were associated with reduced plasma VEGF levels in most infants with severe retinopathy of prematurity (ROP) at 2 and 4 weeks after injection. However, no association was observed between total bevacizumab dose administered and reductions in plasma VEGF levels.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Intravitreal bevacizumab effectively treats severe retinopathy of prematurity (ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth factor (VEGF), potentially causing detrimental effects on developing organs in the premature infant. OBJECTIVE: To evaluate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895318/

データ提供：米国国立医学図書館（NLM）

Low-Dose Bevacizumab for Retinopathy of Prematurity: A Balancing Act

Retinopathy of prematurity (ROP) is a serious eye condition that can affect premature infants. Bevacizumab, a drug used to treat ROP, is like a magic potion, but it can also have unintended consequences. This study investigates the potential impact of low-dose bevacizumab on premature infants, particularly its effect on plasma bevacizumab and VEGF levels. They found that even low doses of bevacizumab can lead to reduced VEGF levels, potentially affecting the developing organs of these fragile infants. It's like carefully navigating a delicate ecosystem, ensuring a balance between the benefits and risks of treatment.

Balancing Act: Navigating the Desert of Drug Effects

The study highlights the importance of carefully considering the potential risks and benefits of low-dose bevacizumab for premature infants. It's like a careful camel caravan traversing a delicate desert landscape. While it offers a potential solution for ROP, it's crucial to weigh its potential impact on overall infant development. Further research is needed to understand the long-term effects of this treatment on neurodevelopment and retinal structure.

Long-Term Impact: Ensuring a Safe Journey

This study reminds us that even the smallest doses of medications can have significant effects on developing organisms. It's like a tiny pebble tossed into a vast desert, creating ripples that can impact the entire landscape. We need to proceed with caution and continue exploring the long-term implications of low-dose bevacizumab to ensure the best possible outcomes for premature infants.

Dr.Camel's Conclusion

This study is an important step in understanding the complex interplay of medications and developing organisms. Like the delicate balance of a desert ecosystem, we need to carefully consider the potential effects of our interventions to ensure the well-being of our most vulnerable patients.

Date :
  1. Date Completed 2022-04-25
  2. Date Revised 2023-03-17
Further Info :

Pubmed ID

35446359

DOI: Digital Object Identifier

PMC8895318

Related Literature

Article Analysis
・Effects of bevacizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.